COVID-19: Potential of Microalgae Derived Natural Astaxanthin As Adjunctive Supplement in Alleviating Cytokine Storm
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The pandemic outbreak of Coronavirus disease (COVID-2019) is a potentially fatal and highly contagious disease. Given that in absence of definitive COVID-19 treatment, and the presence of asymptomatic carriers, the conventional intervention measures to curb the rate of infection and deaths will be highly challenging. Accumulating evidences suggest that excessive reactive inflammation, oxidation, and an exaggerated immune response very likely to contribute to its pathology, leads by a violent immune response cytokine storm and subsequent progression to life threatening acute respiratory distress syndrome (ARDS)/acute lung injury (ALI). Microalgae derived natural astaxanthin (nASX), a well-known potent anti-oxidant and broad-spectrum anti-inflammatory compound with impressive safety profile, is protective against cytokine storm, ALI/ARDS. This article summarizes the most likely benefits of nASX may provide as an adjunctive in attenuation of COVID-19 induced health adversaries based on its putative pathogenesis. There is rationale, pre-clinical evidences of effectiveness and evidence of safety from long-time use for other indications to justify possible inclusion of nASX as adjunctive in combination with primary anti-viral drugs therapy will hugely benefit COVID-19 patients by improving their health and reducing recovery time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overview of the immune response
Chaplin, D. D. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.12.980 · Cited by 2,235
Alhazzani, W., Møller, M. H., Arabi, Y. M., Loeb, M., Gong, M. N., Fan, E., Oczkowski, S., Levy, M. M., Derde, L., Dzierba, A., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06022-5 · Cited by 2,105
Zhang, W., Zhao, Y., Zhang, F., Wang, Q., Li, T., Liu, Z., Wang, J., Qin, Y., Zhang, X., Yan, X., et al. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108393 · Cited by 1,266
Nichols, J. A., & Katiyar, S. K. (2010) · Archives of Dermatological Research · doi:10.1007/s00403-009-1001-3 · Cited by 1,103
Jyonouchi, H., Zhang, L., Gross, M., & Tomita, Y. (1994) · Nutrition and Cancer · doi:10.1080/01635589409514303 · Cited by 183
Research works printed but not linked: 67
- P Zhou, 2020, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, 10.1038/s41586-020-2012-7 · DOI · Paper page
- C Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 30183, 10.1016/S0140-6736(20 · doi:10.1016/s0140-6736(20
- C K Wong, 2004, Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome, Clin Exp Immunol, 136, 95, 10.1111/j.1365-2249.2004.02415.x · DOI · Paper page
- Y Chen, 2020, Emerging coronaviruses: Genome structure, replication, and pathogenesis, J Med Virol, 92, 418, 10.1002/jmv.25681 · DOI · Paper page
- P Kidd, 2011, cell membrane nutrient with diverse clinical benefits and anti-aging potential, Altern. Med. Rev, 16, 355
- J Dhinaut, 2017, A dietary carotenoid reduces immunopathology and ehances longevity through an immune depressive effect in an insect model, Scientific Rep, 10.1038/s41598-017-12769-7 · DOI
- X Cai, 2019, Astaxanthin prevents against lipopolysaccharide-induced acute lung injury and sepsis via inhibiting activation of MAPK/NF-?B, Am J Transl Res, 11
- X Li, 2020, Molecular immune pathogenesis and diagnosis of COVID-19, Journal of Pharmaceutical Analysis, 10.1016/j.jpha.2020.03.001 · DOI · Paper page
- D Wang, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, JAMA, 10.1001/jama.2020.1585 · DOI · Paper page
- Z Xu, 2020, Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory medicine, 10.1016/s2213-2600(20)30076-x · DOI · Paper page
- W J Guan, 2020, Clinical Characteristics of Coronavirus Disease 2019 in China. The New England journal of medicine, 10.1056/NEJMoa2002032 · DOI · Paper page
- A E Williams, 2014, The mercurial nature of neutrophils: still an enigma in ARDS?, Am. J. Physiol. Lung Cell Mol. Physiol, 10.1152/ajplung.00311.2013 · DOI · Paper page
- Y Shi, 2020, COVID-19 infection: the perspectives on immune responses, Cell Death & Differ, 10.1038/s41418-020-0530-3 · DOI · Paper page
- Y Liu, 2020, Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury, Sci. China Life Sci, 63, 364, 10.1007/s11427-020-1643-8 · DOI · Paper page
- R O Bonow, 2020, Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality, JAMA Cardiol, 10.1001/jamacardio.2020.1105 · DOI · Paper page
- N Chen, 2020, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet, 395, 507, 10.1016/s0140-6736(20)30211-7 · DOI · Paper page
- K W Chan, COVID-19: An update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese -Western medicine for the management of 2019 novel coronavirus disease, 10.1142/s0192415x20500378 · DOI · Paper page
- F Zhou, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, 30566, 10.1016/S0140-6736(20 · doi:10.1016/s0140-6736(20
- G Maclaren, 2020, Preparing for the most critically Ill patients with COVID-19: the potential role of extracorporeal membrane oxygenation, JAMA, 10.1001/jama.2020.2342 · DOI · Paper page
- R Channappanavar, 2016, Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice, Cell Host Microbe, 10.1016/j.chom.2016.01.007 · DOI · Paper page
- R Channappanavar, IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes, J. Clin. Invest, 10.1172/jci126363 · DOI · Paper page
- R Channappanavar, Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology, Semin. Immunopathol, 10.1007/s00281-017-0629-x · DOI · Paper page
- 10.1007/s00281-017-0629-x · DOI · Paper page
- H Lu, 2020, Drug treatment options for the 2019-new coronavirus (2019-nCoV), Biosci. Trends, 10.5582/bst.2020.01020 · DOI · Paper page
- Y M Arabi, Treatment of Middle East respiratory syndrome with a combination of lopinavir/ ritonavir and interferon-?1b (MIRACLE trial): statistical analysis plan for a recursive two stage group sequential randomized controlled trial, 10.1186/s13063-019-3846-x · DOI · Paper page
- J Gao, 2020, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci. Trends, 14, 10.5582/bst.2020.01047 · DOI · Paper page
- M Wang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, 10.1038/s41422-020-0282-0 · DOI · Paper page
- K Zhang, 2020, Is traditional Chinese medicine useful in the treatment of COVID-19?, Am J Emerg Med, 10.1016/j.ajem.2020.03.046 · doi:10.1016/j.ajem.2020.03.046
- J T Poston, 2020, Management of critically ill adults with COVID-19, JAMA. Crit Care Med
- R Zhang, 2020, COVID-19: Melatonin as a potential adjuvant treatment, Life Sciences, 10.1016/j.lfs.2020.117583 · DOI · Paper page
- R R Ambati, 2014, Astaxanthin: Source, Extraction, Stability, Biological activities and Its commercial applications -a review, Mar. Drugs, 10.3390/md12010128 · DOI · Paper page
- F J Pashkow, 2008, Astaxanthin: A novel potential treatment for oxidative stress and inflammation in cardiovascular disease, Am. J. Cardiol, 101, 58, 10.1016/j.amjcard.2008.02.010 · DOI · Paper page
- M P Barros, Neuroprotective properties of the marine carotenoid astaxanthin and omega-3 fatty acids, and perspectives for the natural combination of both in krill oil, Nutrients, 2014, 1293, 10.3390/nu6031293 · DOI
- B P Chew, The immune system and disease, Carotenoids: Nutrition and Health
- J S Park, 2010, Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans, Nutr. Metab, 7, 18, 10.1186/1743-7075-7-18 · DOI · Paper page
- G N Coral-Hinostroza, 2004, Plasma appearance of unesterified astaxantin geometrical E/Z and optical R/S isomers in men given single doses of a mixture of optical 3 and 3'R/S isomers of astaxanthin fatty acyl diesters, Comp Biochem Physiol C Toxicol Pharmacol, 139, 99, 10.1016/j.cca.2004.09.011 · DOI
- B Capelli, 2019, Astaxanthin sources: suitability for human health and nutrition, Functional Foods in Health and Disease, 9, 10.31989/ffhd.v9i6.584 · DOI · Paper page
- E G Rosenbaugh, 2013, Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases, Am J Physiol Regul Integr Comp Physiol, 10.1152/ajpregu.00395.2012 · DOI
- M Sztretye, 2019, Astaxanthin: A Potential Mitochondrial-Targeted Antioxidant Treatment in Diseases and with Aging, Oxidative Medicine and Cellular Longevity, 10.1155/2019/3849692 · DOI · Paper page
- H Cui, 2012, Oxidative stress, mitochondrial dysfunction, and aging, Journal of Signal Transduction, 10.1155/2012/646354 · DOI · Paper page
- R Hoffman, Astaxanthin extends lifespan via altered biogenesis of the mitochondrial respiratory chain complex III, 10.1101/698001 · DOI
- H Wu, 2015, Astaxanthin as a Potential Neuroprotective Agent for Neurological Diseases, 5750, 10.3390/md13095750 · DOI · Paper page
- Y Nishida, 2007, Quenching activities of common hydrophilic and lipophilic antioxidants against singlet oxygen using chemiluminescence detection system, Carotenoid Science, 11, 16
- X Zhang, 2018, Astaxanthin mitigates subarachnoid hemorrhage injury primarily by increasing sirtuin 1 and inhibiting the Toll-like receptor 4 signaling pathway, 10.1096/fj.201800642rr · DOI
- M Miyachi, 2015, Anti-inflammatory effects of astaxanthin in the human gingival keratinocyte line NDUSD1
- S J Lee, 2003, Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(kappa)B kinasedependent NF-kappaB activation, Mol Cells, 16, 97, 10.1016/S1016-8478(23)13772-1 · DOI · Paper page
- K C Chan, 2012, Anticoagulatory and anti-inflammatory effects of astaxanthin in diabetic rats, J Food Sci, 77, 76, 10.1111/j.1750-3841.2011.02558.x · DOI
- M Yamamoto, 2010, Lipid A receptor TLR4-mediated signaling pathways, Adv Exp Med Biol, 667, 59
- J C Merrill, 2011, Whole-body deletion of LPS-induced TNFalpha factor (LITAF) markedly improves experimental endotoxic shock and inflammatory arthritis, Proc Natl Acad Sci U S A, 108, 21247, 10.1073/pnas.1111492108 · doi:10.1073/pnas.1111492108
- Z W Zhang, 2016, Mitochondrion-Permeable Antioxidants to Treat ROS-BurstMediated Acute Diseases, 10.1155/2016/6859523 · DOI · Paper page
- Lin, 2016, Stimulates Immune Responses by Enhancing IFN-and IL-2 Secretion in Primary Cultured Lymphocytes in Vitro and ex Vivo, 10.3390/ijms17010044 · DOI
- D Gao, 2019, Astaxanthin attenuate iohexol-induced human proximal renal tubular epithelial cells injury via the ROS/NLRP3 inflammasome signal pathway, SDRP Journal of Food Science & Technology, 4, 10.25177/jfst.4.3.ra.503 · doi:10.25177/jfst.4.3.ra.503
- S Fakhri, 2019, The Neuroprotective Effects of Astaxanthin: Therapeutic Targets and Clinical Perspective, Molecules, 24, 10.3390/molecules24142640 · DOI · Paper page
- X Song, 2014, Astaxanthin inhibits apoptosis in alveolar epithelial cells type II in vivo and in vitro through the ROS-dependent mitochondrial signaling pathway, J. Cell. Mol. Med, 18, 2198, 10.1111/jcmm.12347 · DOI
- 2020, Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury, 10.1016/S0140-6736(20)30317-2 · DOI · Paper page
- M A Matthay, 2020, Treatment of severe acute respiratory syndrome from COVID-19, The Lancet, 30121, 10.1016/S2213-2600 · doi:10.1016/s2213-2600
- A S Abdulamir, 2020, The possible immunological pathway for the variable immunopathogenesis of COVID-19 infections among healthy adults, elderly and children, Electron J Gen Med, 17, 10.29333/ejgm/7850 · DOI · Paper page
- J S Park, 2010, Astaxanthin uptake in domestic dogs and cats, Nutrition & Metabolism, 7, 10.1186/1743-7075-7-52 · DOI
- B P Chew, 1999, Dietary b-carotene and astaxanthin but not canthaxanthin stimulate splenocyte function in mice, Anticancer Re, 19, 5223
- M Bennedsen, 1999, Treatment of H. pylori infected mice with antioxidant astaxanthin reduces gastric inflammation, bacterial load and modulates cytokine release by splenocytes, Immunol Lett, 70, 185, 10.1016/s0165-2478(99)00145-5 · DOI · Paper page
- Acm Boon, 2002, Invitro effect of bioactive compounds on Influenza Virus specific B-and T-cell responses, Scan J Immunology, 55, 24, 10.1046/j.1365-3083.2002.01014.x · DOI
- Sal Sep�lveda, 2019, Antioxidants benefits in hepatitis C infection in the new DAAs era, Annals of Hepatology, 18, 410, 10.1016/j.aohep.2019.04.004 · doi:10.1016/j.aohep.2019.04.004
- M Wang, 2013, Astaxanthin ameliorates lung fibrosis in vivo and in vitro by preventing transdifferentiation, inhibiting proliferation and promoting apoptosis of activated cells, Food and Chem. Toxicol, 450, 10.1016/j.fct.2013.03.004 · DOI
- W Xu, Astaxanthin protects OTA-induced lung injury in mice through Nrf2/NF-kB pathway, Toxins, 2019, 10.3390/toxins11090540 · DOI
- W Diao, 2019, Astaxanthin protects against renal fibrosis through inhibiting myofibroblast activation and promoting CD8 + T cell recruitment, 10.1016/j.bbagen.2019.05.020 · DOI
- R G Fassett, 2011, Astaxanthin: A potential therapeutic agent in cardiovascular disease, 9, 447, 10.3390/md9030447 · DOI · Paper page
- H Hashimoto, 2019, Effects of astaxanthin on VEGF level and antioxidation in human aqueous humor: difference by sex, 10.3164/jcbn.18-110 · doi:10.3164/jcbn.18-110
Cited by
Microalgae: therapeutic potentials and applications
Khavari, F., Saidijam, M., Taheri, M., & Nouri, F. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06422-w · Cited by 257
Microalgal Cell Biofactory—Therapeutic, Nutraceutical and Functional Food Applications
Kiran, B. R., & Venkata Mohan, S. (2021) · Plants · doi:10.3390/plants10050836 · Cited by 124
“, 100 times higher than alpha-tocopherol, 6000 times as much as vitamin C, 800 times as much as coenzyme Q10, 550 times as much as vitamin E, 200 times as much as polyphenols, 150 times as much as anthocyanins, and 75 times as much as alpha-lipoic acid [33].”
BackgroundKaur, M., Bhatia, S., Gupta, U., Decker, E., Tak, Y., Bali, M., Gupta, V. K., Dar, R. A., & Bala, S. (2023) · Phytochemistry Reviews · doi:10.1007/s11101-022-09848-7 · Cited by 95
Algae-derived bioactive molecules for the potential treatment of SARS-CoV-2
Alam, M. A., Parra-Saldivar, R., Bilal, M., Afroze, C. A., Ahmed, M. N., Iqbal, H. M. N., & Xu, J. (2021) · Molecules · doi:10.3390/molecules26082134 · Cited by 69
“Astaxanthin is considered GRAS and is approved by the United States Food and Drug Administration for human consumption [45].”
BackgroundAyub, A., Rahayu, F., Khamidah, A., Antarlina, S. S., Iswari, K., Supriyadi, K., Mufidah, E., Singh, A., Chopra, C., & Wani, A. K. (2025) · Discover Applied Sciences · doi:10.1007/s42452-025-06916-3 · Cited by 29
“The global focus remains on combatting the coronavirus disease (COVID-19) pandemic, a paramount health concern necessitating effective therapeutic interventions to curtail the staggering toll of lives lost worldwide [164].”
Metadata
- Authors
- Talukdar, J., Dasgupta, S., Nagle, V., & Bhadra, B.
- Venue
- SSRN Electronic Journal
- Publisher
- Elsevier BV
- Published
- 2020
- ISSN
- 1556-5068 (ISSN-L)
- OpenAlex
- W3021868697
- Cited by
- 57
- References
- 5
- Type
- posted content
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.